caa a22 4500 60624056X CHVBK 20210128101308.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s00508-015-0833-4 doi (NATIONALLICENCE)springer-10.1007/s00508-015-0833-4 Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment [Elektronische Daten] [Kurt Derfler, Sabine Steiner, Helmut Sinzinger] Summary: The prevalence of familial disorders of lipid metabolism in Europe is higher than believed so far. In severely affected patients in whom conventional combined lipid lowering agents are insufficient to achieve target values, patients being intolerant to all the available members of the statin family as well as in patients with elevated lipoprotein(a) (100mg/dl) and progression of atherosclerotic vascular disease, despite even normal low-density lipoproteins (LDL)-cholesterol values, lipoprotein-apheresis treatment is indicated. The Austrian Apheresis Consensus compares the inclusion criteria for patients to be treated in Austria with those from Italy, Germany, Spain, Japan, UK and the United States. The cut off level of 100mg/dl for lipoprotein(a) is higher in Austria as compared to the aforementioned countries (50 or 60mg/dl, respectively). The available clinical data reveal that regular weekly lipoprotein apheresis not only results in a significant lowering of the respective atherogenic lipid and lipoprotein parameters, but also in a significant decrease in clinical events and interventions. The underlying mechanisms such as non-lipid effects, side effects as well as the different available treatment principles are compared. For patients meeting the inclusion criteria, lipoprotein apheresis is a safe and effective therapy significantly reducing vascular events. Springer-Verlag Wien, 2015 Lipoprotein-apheresis nationallicence Familial hypercholesterolemia nationallicence Lipoprotein(a) nationallicence Austrian consensus nationallicence Vascular events nationallicence Derfler Kurt Department of Internal Medicine III, Division of Nephrology and Dialysis, AKH, Währinger Gürtel 18-20, 1090, Vienna, Austria aut Steiner Sabine Institute for Diagnosis and Treatment of Atherosclerosis and Lipid Disorders (ATHOS), Nadlergasse 1/2/11, 1090, Vienna, Austria aut Sinzinger Helmut Institute for Diagnosis and Treatment of Atherosclerosis and Lipid Disorders (ATHOS), Nadlergasse 1/2/11, 1090, Vienna, Austria aut Wiener klinische Wochenschrift Springer Vienna 127/15-16(2015-08-01), 655-663 0043-5325 127:15-16<655 2015 127 508 https://doi.org/10.1007/s00508-015-0833-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-015-0833-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Derfler Kurt Department of Internal Medicine III, Division of Nephrology and Dialysis, AKH, Währinger Gürtel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Steiner Sabine Institute for Diagnosis and Treatment of Atherosclerosis and Lipid Disorders (ATHOS), Nadlergasse 1/2/11, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Sinzinger Helmut Institute for Diagnosis and Treatment of Atherosclerosis and Lipid Disorders (ATHOS), Nadlergasse 1/2/11, 1090, Vienna, Austria aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/15-16(2015-08-01), 655-663 0043-5325 127:15-16<655 2015 127 508